EverLife Capital · Membership

Longevity Biotech Is Moving From The Lab Into People. Know Which Companies Are Doing It, And How To Judge Them.

Members get my 25-gate Dual ROI scores on the companies making news, plus two short lessons a week that build your own judgment. What each breakthrough could mean for health, and what an investor can see about the company behind it, in plain English.

See What You Get ↓

Education only. Not investment or medical advice.

What You Get

Dual ROI scores on the companies in the news. Human benefit and financial potential, scored on 25 gates: the evidence, funding, valuation and ownership.
The companies I'm watching most closely. Dated entries on the Research Tracker, Scout list and Watchlist, with the evidence, assumptions and open questions.
Two short lessons a week. Learn one skill in plain English, apply it to a real company, then compare with my reasoning.
Follow-ups and a dated archive. See what changed, including setbacks, and revisit earlier assessments.
A dated milestone calendar. Trial starts, results and FDA filings the companies have announced.

Short lessons fit around other activities. Full company reviews take more time. New qualifying companies aren't promised every week.

How It Helps You

Save time. I spend the hours on the science, filings and investor pitches. You get what matters in a few minutes.
See the risks before the headline. Small studies, no comparison group, thin cash, dilution.
Question any pitch, including AI summaries. Learn to check claims against their sources.
Decide for yourself. No stock picks and no buy or sell calls. The judgment stays yours.

Why Now

In the last few weeks:

A company reported the first results from a cell-reprogramming therapy given to people (Oct 8).
The maker of Ozempic reported its drug lowered organs' biological age in more than 10,000 trial participants (preprint, Sept 22).
FDA officials said aging will be featured in the agency's next science-priorities report (early October).

More longevity companies are reaching human trials. Each one deserves to be judged on its own evidence, not its headline.

A Dated, Public Record

Every company I score gets a dated entry that stays public, including setbacks. As of October 17, 2026: 22 companies followed, six with documented clinical or regulatory progress, and one documented clinical setback. These counts are not a success rate or an investment return.

See the dated assessments →

Why I Built EverLife

I lost $10,000 in each of my first two longevity biotech investments. Both sounded promising. After 25 years building a services business, I turned to longevity biotech and built the 25-Gate Framework to judge these companies before backing them. EverLife is the shortcut I wish I'd had.

View my LinkedIn →

Start Your 14-Day Free Trial

Annual: $399/year after your trial. Save $201 versus twelve monthly payments.
Monthly: $50/month after your trial. Cancel future renewals anytime.

Card required. Cancel before day 14 and pay nothing. After 14 days, your plan renews at $50/month or $399/year until you cancel.

Six-Month Learning Guarantee

Give yourself six months to explore the framework, the company research, and the lessons. If you don’t feel better equipped to understand longevity biotechs, recognize important risks, and make your own informed assessments, email me for a full refund of your membership fees. No questions asked.

Email [email protected] anytime through 30 days after the six-month anniversary of your first paid membership charge. We’ll refund all membership fees paid during that period and cancel future renewals, including a full refund of an annual membership payment. This guarantee covers satisfaction with the membership. It does not cover investment losses or promise financial returns.

Save $201/year with the annual plan